What do systematic reviews say?

Stiripentol vs add‐on placebo

Add‐on stiripentol showed no clear difference in ≥ 50% reduction in seizure frequency compared with add‐on placebo (low certainty).

• Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  RR 1.51 [0.81, 2.82]
  1 study · 32 participants
  Low

Stiripentol vs add‐on placebo

Add‐on stiripentol showed no clear difference in seizure freedom compared with add‐on placebo (low certainty).

• Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  RR 1.18 [0.31, 4.43]
  1 study · 32 participants
  Low

Stiripentol vs add‐on placebo

Add‐on stiripentol may leads to higher ≥ 1 adverse effects compared with add‐on placebo (low certainty).

• Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  RR 2.65 [1.08, 6.47]
  1 study · 32 participants
  Low

Stiripentol vs add‐on placebo

Add‐on stiripentol showed no clear difference in neurological adverse effects compared with add‐on placebo (low certainty).

• Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  RR 2.65 [0.88, 8.01]
  1 study · 32 participants
  Low

Stiripentol vs add‐on placebo

• Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 32 participants
  GRADE not reported

Stiripentol vs add‐on placebo

Add‐on stiripentol showed no clear difference in dropouts compared with add‐on placebo (low certainty).

• Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  RR 0.66 [0.3, 1.47]
  1 study · 32 participants
  Low

Stiripentol vs add‐on placebo

The review found no eligible studies for this question.

• Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found